

References

1. Chinese Center for Disease Control and Prevention. Epidemic update and risk assessment of 2019 Novel Coronavirus. Available at: <http://www.chinacdc.cn/yrdgz/202001/P020200128523354919292.pdf>
2. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. *Eurosurveillance*. 2020;25(5):2000062. Available at: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.5.2000062>
3. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *JAMA*. 2020 Available at: <https://doi.org/10.1001/jama.2020.4621>
4. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 2020 May 5;172(9):577-82. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32150748>
5. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020 2020/05/01;581(7809):465-9. Available at: <https://doi.org/10.1038/s41586-020-2196-x>
6. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. *Clinical Infectious Diseases*. 2020;71(10):2663-6. Available at: <https://doi.org/10.1093/cid/ciaa638>
7. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *European Journal of Clinical Microbiology & Infectious Diseases*. 2020 2020/06/01;39(6):1059-61. Available at: <https://doi.org/10.1007/s10096-020-03913-9>
8. Weiss A, Jellingsø M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis. *EBioMedicine*. 2020 Jul 22;58:102916. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374142/pdf/main.pdf>
9. Health Information and Quality Authority. Evidence summary for the duration of infectiousness in those that test positive for SARS-CoV-2 RNA. 15 September 2020. Dublin: HIQA; 2020. Available at: <https://www.hiqa.ie/reports-and-publications/health-technology-assessment/duration-infectiousness-sars-cov-2>
10. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Eurosurveillance*. 2020;25(32):2001483. Available at: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.32.2001483>
11. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Factors affecting COVID-19 period of communicability – what we know so far. Toronto, Canada: Queen’s Printer for Ontario; 2021. Available at: <https://www.publichealthontario.ca/en/diseases-and-conditions/infectious-diseases/respiratory-diseases/novel-coronavirus/what-we-know>

12. Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2021 Feb;27(2):387-9.
13. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nature communications*. 2021 Jan 11;12(1):267. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801729/pdf/41467_2020_Article_20568.pdf
14. Benefield AE, Skrip LA, Clement A, Althouse RA, Chang S, Althouse BM. SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of coronavirus viral load from 66 studies. *medRxiv [Preprint]*. 30 September 2020; Available at: <https://www.medrxiv.org/content/10.1101/2020.09.28.20202028v1>
15. Lewis N, Duca L, Marcenac P, Dietrich E, Gregory C, Fields V, et al. Characteristics and Timing of Initial Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2, Utah, USA. *Emerging Infectious Disease journal*. 2021;27(2):352. Available at: https://wwwnc.cdc.gov/eid/article/27/2/20-3517_article
16. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*. 2021 Jan;2(1):e13-e22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33521734>
17. Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. *Infection control and hospital epidemiology*. 2020;1-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/33077007>
18. Heylen L, Oris E, Wollants E, Maes P, Van Kerrebroeck M, Peeters J, et al. 128 days of SARS-CoV-2 viral shedding in a haemodialysis patient. *Clinical kidney journal*. 2021;14(4):1284-6. Available at: <https://doi.org/10.1093/ckj/sfab004>
19. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell*. 2020 Dec 23;183(7):1901-12.e9.
20. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *New England Journal of Medicine*. 2020;383(23):2291-3. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMc2031364>
21. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients. *Clinical Infectious Diseases*. 2020;71(16):2249-51. Available at: <https://doi.org/10.1093/cid/ciaa460>
22. Zhou B, She J, Wang Y, Ma X. Duration of Viral Shedding of Discharged Patients With Severe COVID-19. *Clinical Infectious Diseases*. 2020;71(16):2240-2. Available at: <https://doi.org/10.1093/cid/ciaa451>
23. Molina LP, Chow SK, Nickel A, Love JE. Prolonged Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an Obstetric Patient With Antibody Seroconversion. *Obstetrics and gynecology*. 2020 Oct;136(4):838-41.

24. Korea Central Disaster Control and Prevention. Findings from Investigation and analysis of re-positive cases. Seoul: KCDC; 2020. Available at: https://www.mofa.go.kr/eng/brd/m_22743/view.do?seq=3&srchFr=&srchTo=&srchWord=&srchTp=&multi_itm_seq=0&itm_seq_1=0&itm_seq_2=0&company_cd=&company_nm=&page=1&titleNm=
25. Liu W-D, Chang S-Y, Wang J-T, Tsai M-J, Hung C-C, Hsu C-L, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. *Journal of Infection*. 2020;2020/08/01/;81(2):318-56. Available at: <https://www.sciencedirect.com/science/article/pii/S0163445320301900>
26. Yan D, Zhang X, Chen C, Jiang D, Liu X, Zhou Y, et al. Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis. *Frontiers in public health*. 2021;9:652842-. Available at: <https://pubmed.ncbi.nlm.nih.gov/33816427>
27. Morone G, Palomba A, Iosa M, Caporaso T, De Angelis D, Venturiero V, et al. Incidence and Persistence of Viral Shedding in COVID-19 Post-acute Patients With Negativized Pharyngeal Swab: A Systematic Review. *Front Med (Lausanne)*. 2020;7:562. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483760/pdf/fmed-07-00562.pdf>
28. Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. *Proceedings of the National Academy of Sciences*. 2021;118(8):e2017962118. Available at: <https://www.pnas.org/content/pnas/118/8/e2017962118.full.pdf>
29. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*. 2020;2020/05/01/;20(5):565-74. Available at: <https://www.sciencedirect.com/science/article/pii/S1473309920301961>
30. Yonker LM, Neilan AM, Bartsch Y, Patel AB, Regan J, Arya P, et al. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. *The Journal of pediatrics*. 2020 Dec;227:45-52.e5.
31. European Centre for Disease Prevention and Control. Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination. 29 March 2021. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/publications-data/sars-cov-2-transmission-newly-infected-individuals-previous-infection#no-link>
32. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *The Lancet*. 2021;2021/04/10/;397(10282):1351-62. Available at: <https://www.sciencedirect.com/science/article/pii/S0140673621006280>
33. European Centre for Disease Prevention and Control. Reinfection with SARS-CoV-2: considerations for public health response. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-reinfection-sars-cov-2>
34. Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. *Clin Microbiol Infect*. 2021 Mar;27(3):315-8. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33285276>

35. Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. *Infect Dis (Lond)*. 2021 Jan 28;1-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33508989>
36. SeyedAlinaghi S, Oliaei S, Kianzad S, Afsahi AM, MohsseniPour M, Barzegary A, et al. Reinfection risk of novel coronavirus (COVID-19): A systematic review of current evidence. *World J Virol*. 2020 Dec 15;9(5):79-90. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33363000>
37. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2020 Nov 26;10(1):20692. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33244060>
38. Gidari A, Nofri M, Saccarelli L, Bastianelli S, Sabbatini S, Bozza S, et al. Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature. *European Journal of Clinical Microbiology & Infectious Diseases*. 2021 2021/01/01;40(1):1-12. Available at: <https://doi.org/10.1007/s10096-020-04057-6>
39. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nature communications*. 2020 Sep 17;11(1):4704. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32943637>
40. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. *PLoS One*. 2020;15(12):e0244126. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33382764>
41. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. *PLoS One*. 2021;16(1):e0245532. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33493185>
42. Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? *Vaccine X*. 2020 Dec 11;6:100076. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32875286>
43. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*. 2020 Apr;5(4):562-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32094589>
44. Health Information and Quality Authority. Duration of immunity (protection from reinfection) following SARS-CoV-2 infection. Dublin: HIQA; 2021. Available at: <https://www.hiqa.ie/reports-and-publications/health-technology-assessment/duration-protective-immunity-protection>
45. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*. 2021 Feb 11;384(6):533-40. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33369366>
46. Hall V, Foulkes S, Charlett A, Atti A, Monk E, Simmons R, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. *medRxiv*. 2021:2021.01.13.21249642. Available at: <https://www.medrxiv.org/content/medrxiv/early/2021/01/15/2021.01.13.21249642.full.pdf>

47. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, et al. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv [Preprint]. 8 February 2021; Available at: <https://www.medrxiv.org/content/10.1101/2021.01.15.21249731v2>
48. Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. *The Journal of infection*. 2020 Dec 26 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33373652>
49. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet*. 2021 Mar 17 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33743221>
50. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. medRxiv [Preprint]. 20 December 2020; Available at: <https://www.medrxiv.org/content/10.1101/2020.12.18.20248336v1>
51. World Health Organization. Weekly epidemiological update - 25 February 2021. Geneva: WHO; 2021. Available at: <https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update>
52. European Centre for Disease Prevention and Control. Guidance for representative and targeted genomic SARS-CoV-2 monitoring. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/publications-data/guidance-representative-and-targeted-genomic-sars-cov-2-monitoring>
53. Fabiánová K, Kynčl J, Vlčková I, Jiřincová H, Košťálová J, Liptáková M, et al. COVID-19 reinfections. *Epidemiologie, mikrobiologie, imunologie*. 2021;70(1):62-7.
54. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, re-infection and transmissibility associated with SARS-CoV-2 variant B.1.1.7: an ecological study. medRxiv [Preprint]. 21 March 2021; Available at: <https://www.medrxiv.org/content/10.1101/2021.01.28.21250680v2>
55. European Centre for Disease Prevention and Control. Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/publications-data/reinfection-sars-cov-2-implementation-surveillance-case-definition-within-eueea>
56. European Centre for Disease Prevention and Control. Surveillance definitions for COVID-19. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/covid-19/surveillance/surveillance-definitions>
57. European Centre for Disease Prevention and Control. TESSy reporting protocol for COVID-19. Stockholm: ECDC; 2021. Available at: <https://www.ecdc.europa.eu/en/covid-19/surveillance/study-protocols>
58. European Centre for Disease Prevention and Control. COVID-19 country overviews. Stockholm: ECDC; 2021. Available at: <http://covid19-country-overviews.ecdc.europa.eu/>